SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Cellectis S.A. CMVLF OTC

Other OTC • Healthcare • Biotechnology • FR • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Cellectis S.A. (CMVLF) is a Biotechnology company in the Healthcare sector, currently trading at $3.08. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $76M, +1794.8%/yr average growth. Net income is $70M (loss), growing at -8.1%/yr. Net profit margin is -92.7% (negative). Gross margin is 72.5% (-18.3 pp trend).

Balance sheet: total debt is $120M against $76M equity (Debt-to-Equity (D/E) ratio 1.58, leveraged). Current ratio is 1.62 (strong liquidity). Debt-to-assets is 36.9%. Total assets: $325M.

Analyst outlook: 7 / 10 analysts rate CMVLF as buy (70%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 35/100 (Fail), Future 75/100 (Pass), Income 10/100 (Fail).

CMVLF SharesGrow Score Overview

42/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 35/100

Gross margin is + market cap

FUTURE 75/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CMVLF

No analyst coverage available for this stock.

CMVLF: +1794.8%/yr revenue is, -8.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet CMVLF: Debt-to-Equity (D/E) ratio 1.58 (leveraged), Current ratio is 1.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CMVLF: Gross margin is 72.5% (-18.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.

View details →

Analyst outlook: 7 / 10 analysts rate CMVLF as buy (70%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CMVLF: Net profit margin is -92.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.25-5.04

Volume300

Avg Volume (30D)3

Market Cap$222.76M

Beta (1Y)2.71

Share Statistics

EPS (TTM)-0.70

Shares Outstanding$100.28M

IPO Date2014-07-01

Employees216

CEOAndre Choulika

Financial Highlights & Ratios

Revenue (TTM)$75.92M

Gross Profit$55.04M

EBITDA$-21.12M

Net Income$-70.34M

Operating Income$-42M

Total Cash$208.67M

Total Debt$119.91M

Net Debt$56.32M

Total Assets$324.74M

Price / Earnings (P/E)-4.4

Price / Sales (P/S)2.93

Analyst Forecast

Rating ConsensusBuy

Analysts Covering10

Buy 70% Hold 20% Sell 10%

Company Info

CountryFR

ExchangeOther OTC

CurrencyUSD

ISINFR0010425595

Price Chart

CMVLF

Cellectis S.A. ↗ · Other OTC

Healthcare • Biotechnology

1.25 52WK RANGE 5.04

People Also View

Covalon Technologies Ltd.

Small Pharma Inc.

Biotron Limited

Resverlogix Corp.

Mosaic ImmunoEngineering Inc.

Advanced Proteome Therapeutics Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message